ALNEV Share Price

Open 0.90 Change Price %
High 0.90 1 Day -0.02 -2.22
Low 0.88 1 Week -0.05 -5.38
Close 0.88 1 Month -0.05 -5.38
Volume 399403 1 Year -0.28 -24.14
52 Week High 1.37
52 Week Low 0.66
ALNEV Important Levels
Resistance 2 0.90
Resistance 1 0.89
Pivot 0.89
Support 1 0.87
Support 2 0.86
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
AVT 0.09 -10.00%
OXI 0.09 -10.00%
OXI 0.09 -10.00%
STAL 375.02 -8.53%
FED 13.00 -8.52%
FED 13.00 -8.52%
FIPP 0.13 -7.14%
More..

Neovacs SA (EPA: ALNEV)

ALNEV Technical Analysis 1.5
As on 27th Mar 2017 ALNEV Share Price closed @ 0.88 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.84 & Sell for SHORT-TERM with Stoploss of 0.90 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALNEV Target for March
1st Target up-side 1.08
2nd Target up-side 1.2
3rd Target up-side 1.32
1st Target down-side 0.74
2nd Target down-side 0.62
3rd Target down-side 0.5
ALNEV Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neovacs.fr
ALNEV Address
ALNEV
3-5, Impasse Reille
Paris, 75014
France
Phone: 33 1 53 10 93 00
Fax: 33 1 53 10 93 03
ALNEV Latest News
Interactive Technical Analysis Chart Neovacs SA ( ALNEV EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neovacs SA
ALNEV Business Profile
Neovacs S.A., a biotechnology company, focuses on active immunotherapy for autoimmune and inflammatory diseases in France. The company’s product pipeline comprises tumor necrosis factor kinoid for the treatment of rheumatoid arthritis and Crohn’s diseases; interferon a-kinoid to treat lupus; and vascular endothelial growth factor kinoid for the treatment of macular degeneration and cancer. Neovacs S.A. is based in Paris, France.